SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stem Cell Research
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI7/19/2006 2:12:41 PM
   of 495
 
7:31AM Geron announces publication of study results supporting safety and utility of human embryonic stem cell-derived therapeutic product (GERN) 6.15 : Co announces the publication of preclinical studies that support the safety and utility of GRNOPC1, Geron's lead human embryonic stem cell (hESC)-based therapeutic product for the treatment of spinal cord injury. In the studies published in Regenerative Medicine, Dr. Hans Keirstead and his colleagues at the University of California, Irvine, injected GRNOPC1 into the lesion site of rats that received either very mild or moderate spinal cord contusion injuries. GRNOPC1 survived in both the mild and moderate lesion sites, with a broader distribution of transplanted cells and robust remyelination in the more severe injuries, replicating previous studies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News